Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EPS (Basic): 2016-2025

Historic EPS (Basic) for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $2.69.

  • Tg Therapeutics' EPS (Basic) rose 8866.67% to $2.69 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.07, marking a year-over-year increase of 3511.11%. This contributed to the annual value of $0.16 for FY2024, which is 77.78% up from last year.
  • As of Q3 2025, Tg Therapeutics' EPS (Basic) stood at $2.69, which was up 1,315.79% from $0.19 recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' EPS (Basic) peaked at $2.69 during Q3 2025, and registered a low of -$0.70 during Q4 2021.
  • For the 3-year period, Tg Therapeutics' EPS (Basic) averaged around $0.29, with its median value being $0.03 (2025).
  • Its EPS (Basic) has fluctuated over the past 5 years, first tumbled by 96.25% in 2024, then spiked by 8,866.67% in 2025.
  • Tg Therapeutics' EPS (Basic) (Quarterly) stood at -$0.70 in 2021, then climbed by 18.57% to -$0.57 in 2022, then soared by 82.46% to -$0.10 in 2023, then soared by 260.00% to $0.16 in 2024, then soared by 8,866.67% to $2.69 in 2025.
  • Its last three reported values are $2.69 in Q3 2025, $0.19 for Q2 2025, and $0.03 during Q1 2025.